Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Company profile from EODHD, stored Nov 3, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | — | — | — | -$5.6M | -$5.7M |
| Mar 2026filed May 15, 2026 | — | — | — | -$5.3M | -$5.5M |
| Dec 2025filed Feb 17, 2026 | — | — | — | -$5.4M | -$5.5M |
| Sep 2025filed Dec 29, 2025 | — | — | — | -$6.0M | -$6.1M |
| Jun 2025filed Aug 14, 2025 | — | — | — | -$5.5M | -$5.7M |
| Mar 2025filed May 14, 2025 | — | — | — | -$6.4M | -$6.6M |
| Dec 2024filed Feb 14, 2025 | $6.0M | — | — | -$6.9M | -$7.1M |
| Sep 2024 | — | — | — | -$6.1M | -$6.1M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Sep 2025filed Dec 29, 2025 | — | — | — | -$24.8M | -$25.4M |
| Sep 2024filed Jan 13, 2025 | — | — | — | -$26.4M | -$26.9M |
| Sep 2023filed Dec 21, 2023 | — | — | — | -$31.5M | -$32.4M |
| Sep 2022filed Dec 27, 2022 | — | — | — | -$36.1M | -$36.7M |
| Sep 2021filed Dec 21, 2021 | — | — | — | -$36.2M | -$36.4M |
| Sep 2020filed Dec 29, 2020 | $558.7K | +20.7% | -3,093.4% | -$29.0M | -$30.3M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched CVM. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
663,833 shares short
+71,413 shares (+12.1%) vs Sep 30, 2026
3.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
592,420 shares short
-26,842 shares (-4.3%) vs Sep 15, 2026
3.5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
619,262 shares short
-163,197 shares (-20.9%) vs Aug 31, 2026
7.5% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
782,459 shares short
+67,988 shares (+9.5%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
714,471 shares short
-485,883 shares (-40.5%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
1,200,354 shares short
+482,346 shares (+67.2%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind CVM’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
1 for 30 · reverse split
Effective May 20, 2025
Each 30 pre-split shares become 1 post-split share.
Source: EODHD
1 for 25 · reverse split
Effective Jun 15, 2017
Each 25 pre-split shares become 1 post-split share.
Source: EODHD
1 for 10 · reverse split
Effective Sep 25, 2013
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
1 for 10 · reverse split
Effective May 1, 1995
Each 10 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if CVM is in your portfolio and how much it contributes.
Sign inLoading market dates
3 smart-money holders: institutions with a high Holder IQ
Sentiment: neutral
Last trade: buy 73 days ago
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
40 filers reported a long position in CVM for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
87.5%
of the 2M shares 13-F filers reported
Moves vs Q1 2026
5 added1 trimmed
2 new · 2 unchanged
Net shares held
+146.6%
across the 8 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | $595.4K · 572.5K shares | 572.5K | +1,495% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $564.8K · 543.1K shares | 543.1K | +122.9% |
| 3 | CITADEL ADVISORS LLC | $206.4K · 198.5K shares | 198.5K | New |
| 4 | MAI Capital Management | $112.6K · 108.3K shares | 108.3K | +18.6% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | $91.8K · 88.2K shares | 88.2K | +3.4% |
| 6 | COMMONWEALTH EQUITY SERVICES, LLC | $53.5K · 51.4K shares | 51.4K | +191.9% |
| 7 | HRT FINANCIAL LP | $53K · 51.2K shares | 51.2K | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | $51K · 49K shares | 49K | Unchanged |
| 9 | BlackRock, Inc. | $45K · 43.3K shares | 43.3K | Unchanged |
| 10 | BANK OF AMERICA CORP /DE/ | $42.6K · 40.9K shares | 40.9K | -0.2% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inUnlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.